Tagrisso (osimertinib) eventually stops controlling cancer growth in most patients, typically after a median of about 18 to 19 months when used as a first-line treatment. When that happens, the next steps involve figuring out why the drug stopped working and choosing a follow-up treatment based on those findings. The landscape of options after Tagrisso has expanded significantly in recent years, and what your oncologist recommends will depend heavily on the specific biological changes driving your cancer’s resistance.
Why Tagrisso Stops Working
Cancer cells are constantly mutating, and over time they find ways around the drug’s blockade. These resistance mechanisms generally fall into two categories. The first is “on-target” resistance, where the cancer develops new mutations in the same gene Tagrisso was designed to block. The most well-known example is a mutation called C797S, found in roughly 7% of patients at progression. The second category is “off-target” resistance, where the cancer activates entirely different growth pathways to bypass the drug. MET amplification (about 4% of cases) and mutations in genes like PIK3CA (about 9%) and BRAF (about 3%) are common examples.
In a smaller but important subset of patients, around 16%, the cancer transforms into a different cell type entirely, such as small cell lung cancer or squamous cell carcinoma. This histologic transformation changes the biology of the tumor so fundamentally that it requires a different treatment approach altogether.
Testing to Guide Your Next Treatment
Once Tagrisso stops working, your oncologist will likely recommend a new biopsy to identify what’s driving the resistance. This is a critical step because the specific mechanism determines which treatment has the best chance of working next. There are two main options: a tissue biopsy, where a sample is taken directly from the tumor, and a liquid biopsy, which analyzes tumor DNA circulating in your blood.
Each method has strengths and blind spots. Liquid biopsy is less invasive and can reliably detect certain mutations in the EGFR gene itself, picking up C797S mutations about 63% of the time when they’re present. But it’s much less effective at finding MET amplification (only about 22% detection) and cannot detect histologic transformation at all. Tissue biopsy catches a wider range of resistance mechanisms, identifying actionable changes in about 40% of patients compared to 20% with liquid biopsy alone. For a comprehensive picture, many oncologists pursue both when feasible, using the blood test as a quick screen and the tissue biopsy to fill in gaps.
Chemotherapy as a Standard Option
For years, platinum-based chemotherapy combined with pemetrexed was the default next step after Tagrisso. It remains the backbone of post-Tagrisso treatment and is often the comparator against which newer options are measured. On its own, this chemotherapy regimen provides a median progression-free survival of about 4.2 months and a response rate of roughly 36%.
One approach that has shown real promise is continuing Tagrisso alongside chemotherapy rather than dropping it entirely. In a study of patients who progressed on osimertinib, those who kept taking it while adding chemotherapy had a median progression-free survival of 10.1 months, compared to 5.9 months for patients who switched to chemotherapy without osimertinib. Overall survival also improved: 17.0 months versus 12.8 months. The rationale is that even when Tagrisso can no longer fully control the cancer, it may still be suppressing a portion of the tumor cells that remain sensitive to it.
Newer Targeted Combinations
The most significant recent advance for post-Tagrisso treatment comes from the MARIPOSA-2 trial, which tested adding a targeted antibody called amivantamab to chemotherapy. Amivantamab works by blocking two growth signals that lung cancer cells commonly exploit when they develop resistance.
Patients who received amivantamab plus chemotherapy had a median progression-free survival of 6.3 months, and those who received a triple combination of amivantamab, lazertinib (another targeted drug), and chemotherapy reached 8.3 months. Both were significantly better than chemotherapy alone at 4.2 months. Response rates nearly doubled as well: 64% and 63% for the combination arms versus 36% for chemotherapy alone. These results led to regulatory approvals that have made amivantamab-based combinations a new standard of care for many patients progressing on Tagrisso.
When Specific Mutations Are Found
If testing reveals MET amplification as the resistance driver, your oncologist may recommend adding a MET-targeting drug to osimertinib rather than switching to chemotherapy. Early case series have explored combining osimertinib with MET inhibitors like capmatinib, and multiple early-phase studies have investigated this dual-blockade approach. The logic is straightforward: keep Tagrisso working against the original EGFR mutation while adding a second drug to shut down the escape route the cancer found. This precision approach isn’t available for every resistance mechanism, but when the right target is identified, it can be effective.
Antibody-Drug Conjugates on the Horizon
A newer class of drugs called antibody-drug conjugates, or ADCs, is being actively tested for patients who have progressed on Tagrisso. These work like guided missiles: an antibody homes in on a specific protein on the cancer cell’s surface and delivers a potent dose of chemotherapy directly to it, limiting damage to healthy tissue.
The furthest along is patritumab deruxtecan, which targets a protein called HER3 found on many EGFR-mutant lung cancers. It’s currently in a large phase III trial called HERTHENA-Lung02. Other ADCs in development include datopotamab deruxtecan and a bispecific ADC called BL-B01D1 that targets both EGFR and HER3 simultaneously. These are not yet standard options, but they represent a growing pipeline that may offer additional choices in the near future.
What the Treatment Timeline Looks Like
After Tagrisso progression, there’s typically a period of a few weeks for re-biopsy and molecular testing before starting a new treatment. Some patients experience a gradual, slow progression where their oncologist may recommend staying on Tagrisso temporarily, especially if the cancer is growing in only one or two spots that can be treated with localized radiation. Others have more widespread progression that requires a faster transition to the next line of therapy.
With current standard options, second-line treatment after Tagrisso typically keeps the cancer in check for somewhere between 6 and 10 months, depending on the regimen. Overall survival from the start of second-line treatment ranges from roughly 13 to 17 months, though these are median figures and individual outcomes vary widely. Patients whose cancer has an identifiable, targetable resistance mechanism often fare better because their treatment can be more precisely matched to the biology driving their disease. This is one of the strongest arguments for thorough molecular testing at the time of progression.